SUBSCRIBE: Print / eNewsletter
Current Era Means More AML Treatment Options for Elderly
Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.
Unique Case Documents Involution of Nevi on BRAF/MEK Inhibitors
In this interview we discuss a patient who experienced regression of BRAF-inhibitor-induced eruptive melanocytic nevi following concomitant addition of a MEK inhibitor.
Quality-of-Life Issues Important in Neuro-Oncologic Treatment
As part of our Society of Neuro-Oncology annual meeting coverage, we discuss quality of life issues and neurologic rehabilitation in patients with neuro-oncologic diseases.
The Soy, Breast Cancer Connection
In this interview we discuss the link between soy consumption and breast cancer, and the impact of soy supplements on gene expression in early-stage disease.
New Targeted Therapies for CLL
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.
ESMO Preview: Treatment of Genitourinary Cancers Rapidly Evolving
As part of our coverage of the 2014 ESMO meeting we discuss recent advances in the treatment of kidney, bladder, and testicular cancers.
CancerLinQ: ASCO Dives Into Big Data
In this interview we discuss the American Society of Clinical Oncology’s (ASCO) health information and patient record initiative called CancerLinQ.
Relevance of pCR in Breast Cancer Trials
As part of our coverage of the ASCO Breast Cancer Symposium we discuss the clinical meaningfulness of pathologic complete response as a surrogate endpoint in breast cancer clinical trials.
Risk Modification Strategies for Breast Cancer
Ahead of the 2014 ASCO Breast Cancer Symposium we discussed genetic and environmental risk factors for breast cancer, as well as interventions that can reduce a patient’s risk.
Androgen Deprivation Therapy in Localized Prostate Cancer
Following studies that found no survival or mortality benefit, we discuss the utility of primary androgen deprivation therapy in localized prostate cancer.